Literature DB >> 21975336

Does gender matter in glioblastoma?

E Verger1, I Valduvieco, Ll Caral, T Pujol, T Ribalta, N Viñolas, T Boget, L Oleaga, Y Blanco, F Graus.   

Abstract

BACKGROUND The clinical outcome of glioblastoma (GBM) patients who receive radiotherapy alone or with chemotherapy is well established. However, little is known about how many patients do not receive this treatment. We consider it is important to investigate why a proportion of operated patients do not receive further treatment after surgery. METHODS We reviewed all consecutive GBM patients operated on in our hospital between January 2000 and December 2008. RESULTS A total of 216 patients with GBM were identified. Fifty-five (25%) did not receive any treatment after surgery. Univariate analysis showed that factors associated with no further treatment after surgery were older than 60 years (p=0.002), of female gender (p=0.03), had a KPS<70 (p<0.001) and had had a biopsy (p<0.001). Multivariate analysis indicated that age =60 years and KPS <70 were independent predictors of no further treatment after surgery. Gender was not an independent variable. However, women in the whole series were older than 60 years (p=0.01), and they had a worse KPS (p=0.02) and more biopsies (p=0.04) than men. In the whole group, median survival time was 10.4 months for men (n=125) vs. 7.2 months for women (n=91), log rank p<0.04. This difference was not observed in the group that was treated after surgery. CONCLUSIONS One out of four patients could not be treated after surgery. Independent predictors were older age and low KPS. These poor risk variables were more frequent in women and their survival was therefore lower than men in our series.

Entities:  

Mesh:

Year:  2011        PMID: 21975336     DOI: 10.1007/s12094-011-0725-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  14 in total

1.  Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma.

Authors:  M J Winger; D R Macdonald; J G Cairncross
Journal:  J Neurosurg       Date:  1989-10       Impact factor: 5.115

2.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

3.  Patterns of care for adults with newly diagnosed malignant glioma.

Authors:  Susan M Chang; Ian F Parney; Wei Huang; Frederick A Anderson; Anthony L Asher; Mark Bernstein; Kevin O Lillehei; Henry Brem; Mitchel S Berger; Edward R Laws
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

4.  A population-based study of glioblastoma multiforme.

Authors:  L Paszat; N Laperriere; P Groome; K Schulze; W Mackillop; E Holowaty
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-09-01       Impact factor: 7.038

Review 5.  The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature.

Authors:  J F Reavey-Cantwell; R I Haroun; M Zahurak; R E Clatterbuck; R J Parker; R Mehta; J P Fruehauf; H Brem
Journal:  J Neurooncol       Date:  2001-12       Impact factor: 4.130

Review 6.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

7.  Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma.

Authors:  Graziella Filippini; Chiara Falcone; Amerigo Boiardi; Giovanni Broggi; Maria G Bruzzone; Dario Caldiroli; Rita Farina; Mariangela Farinotti; Laura Fariselli; Gaetano Finocchiaro; Sergio Giombini; Bianca Pollo; Mario Savoiardo; Carlo L Solero; Maria G Valsecchi
Journal:  Neuro Oncol       Date:  2007-11-09       Impact factor: 12.300

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

9.  Genetic pathways to glioblastoma: a population-based study.

Authors:  Hiroko Ohgaki; Pierre Dessen; Benjamin Jourde; Sonja Horstmann; Tomofumi Nishikawa; Pier-Luigi Di Patre; Christoph Burkhard; Danielle Schüler; Nicole M Probst-Hensch; Paulo César Maiorka; Nathalie Baeza; Paola Pisani; Yasuhiro Yonekawa; M Gazi Yasargil; Urs M Lütolf; Paul Kleihues
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

10.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.

Authors:  Michael Weller; Jörg Felsberg; Christian Hartmann; Hilmar Berger; Joachim P Steinbach; Johannes Schramm; Manfred Westphal; Gabriele Schackert; Matthias Simon; Jörg C Tonn; Oliver Heese; Dietmar Krex; Guido Nikkhah; Torsten Pietsch; Otmar Wiestler; Guido Reifenberger; Andreas von Deimling; Markus Loeffler
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

View more
  4 in total

1.  Integrative and regularized principal component analysis of multiple sources of data.

Authors:  Binghui Liu; Xiaotong Shen; Wei Pan
Journal:  Stat Med       Date:  2016-01-12       Impact factor: 2.373

2.  Hydrogel Environment Supports Cell Culture Expansion of a Grade IV Astrocytoma.

Authors:  Manasi P Jogalekar; Leigh G Cooper; Elba E Serrano
Journal:  Neurochem Res       Date:  2017-06-07       Impact factor: 3.996

3.  Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients.

Authors:  Manal Nicolasjilwan; Ying Hu; Chunhua Yan; Daoud Meerzaman; Chad A Holder; David Gutman; Rajan Jain; Rivka Colen; Daniel L Rubin; Pascal O Zinn; Scott N Hwang; Prashant Raghavan; Dima A Hammoud; Lisa M Scarpace; Tom Mikkelsen; James Chen; Olivier Gevaert; Kenneth Buetow; John Freymann; Justin Kirby; Adam E Flanders; Max Wintermark
Journal:  J Neuroradiol       Date:  2014-07-02       Impact factor: 3.447

4.  Association between giant cell glioblastoma and glioblastoma multiforme in the United States: A retrospective cohort study.

Authors:  Amro K Bin Abdulrahman; Khalid A Bin Abdulrahman; Yousef R Bukhari; Abdulaziz M Faqihi; Juan Gabriel Ruiz
Journal:  Brain Behav       Date:  2019-08-29       Impact factor: 2.708

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.